Scott Smith
Chief Executive Officer presso VIATRIS INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Scott Andrew Smith currently works at Viatris, Inc., as Chief Executive Officer & Director from 2023, Triumvira Immunologics USA, Inc., as Chairman, Biotechnology Innovation Organization, as Director from 2017, BioAtla, Inc., as Director, Apexigen America, Inc., as Director from 2019, and Himalaya Therapeutics, as Director.
Mr. Smith also formerly worked at F-Star Therapeutics, Inc. (United States), as Chairman from 2019 to 2020, Triumvira Immunologics, Inc., as Chairman from 2017 to 2020, Titan Pharmaceuticals, Inc., as Independent Director, Aitia, Inc., as Director, Apexigen, Inc., as Independent Director from 2019 to 2023, Refuge Biotechnologies, Inc., as Director from 2018 to 2022, Celgene Corp., as President & Chief Operating Officer from 2017 to 2018, Pharmacia Corp., as Vice President-Sales, Pharmacia SAS, as Vice President-Marketing, Biovail Pharmaceuticals LLC, as Vice President & General Manager from 2003 to 2008, Pharmacia Canada, Inc., as Vice President, Parke Davis Ltd., as Head-South East Asia Region, and Biovail Pharmaceuticals Canada, as General Manager from 2003 to 2008.
Mr. Smith received his graduate degree from Thunderbird School of Global Management and undergraduate degree from the University of Western Ontario.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
VIATRIS, INC.
0.01% | 04/03/2024 | 85 350 ( 0.01% ) | 1 M $ | 31/03/2024 |
BIOATLA, INC.
0.61% | 31/03/2024 | 292 455 ( 0.61% ) | 1 M $ | 31/03/2024 |
Posizioni attive di Scott Smith
| Società | Posizione | Inizio |
|---|---|---|
| BIOATLA, INC. | Director/Board Member | 01/07/2020 |
| VIATRIS INC. | Chief Executive Officer | 01/04/2023 |
Himalaya Therapeutics
 Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | Director/Board Member | - |
Triumvira Immunologics USA, Inc.
 Triumvira Immunologics USA, Inc. Miscellaneous Commercial ServicesCommercial Services Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018. | Chairman | - |
Apexigen America, Inc.
 Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | Director/Board Member | 05/09/2019 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | 01/06/2017 |
Precedenti posizioni note di Scott Smith
| Società | Posizione | Fine |
|---|---|---|
| APEXIGEN, INC. | Director/Board Member | 23/08/2023 |
Refuge Biotechnologies, Inc.
 Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Director/Board Member | 01/01/2022 |
| TITAN PHARMACEUTICALS, INC. | Director/Board Member | 08/01/2021 |
| ░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Scott Smith
| Thunderbird School of Global Management | Graduate Degree |
| University of Western Ontario | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| BIOATLA, INC. | Health Technology |
| VIATRIS INC. | Health Technology |
| APEXIGEN, INC. | Health Technology |
| Aziende private | 15 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Aitia, Inc.
 Aitia, Inc. Miscellaneous Commercial ServicesCommercial Services GNS Healthcare, Inc. provides analytics solutions for the healthcare industry. The firm offers solutions for electronic health records, claims, clinical and incentive programs, reward, product development solutions for biopharmaceutical, diagnostic, consumer product, and medical device companies and publications, conference abstracts, and presentations. The company was founded by Colin Hill and Iya Khalil in 2000 and is headquartered in Cambridge, MA. | Commercial Services |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
| Pharmacia SAS | |
Biovail Pharmaceuticals LLC
 Biovail Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Biovail Pharmaceuticals, Inc. researches and develops pharmaceutical medicines. The company products include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. The company is headquartered in Bridgewater, NJ. | Health Technology |
| Pharmacia Canada, Inc. | |
| Parke Davis Ltd. | |
F-Star Therapeutics, Inc. (United States)
 F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | Health Technology |
Triumvira Immunologics, Inc.
 Triumvira Immunologics, Inc. Pharmaceuticals: MajorHealth Technology Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada. | Health Technology |
Biovail Pharmaceuticals Canada
 Biovail Pharmaceuticals Canada Medical DistributorsDistribution Services Biovail Pharmaceuticals Canada sells pharmaceutical products. The private company is based in Mississauga, Canada. | Distribution Services |
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Commercial Services |
Triumvira Immunologics USA, Inc.
Triumvira Immunologics USA, Inc. Miscellaneous Commercial ServicesCommercial Services Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018. | Commercial Services |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | Health Services |
- Borsa valori
- Insiders
- Scott Smith
